Dr. David Seth Feldman has been named the new section chief of the renowned Advanced Heart Failure Treatment and Transplantation unit at Newark Beth Israel Medical Center.
Feldman, who brings more than 25 years of extensive research, innovation and clinical expertise, served as the director of cardiovascular & critical care and the director of advanced myocardial and circulatory support at the University of Cincinnati, where he worked with the team to improve overall survival rates for heart failure and heart transplant patients.
Feldman also played a pivotal role in establishing the nationally ranked Heart Failure and Cardiac Transplant Program at Abbott Northwestern Hospital, where he served as director from 2006-2009.
He is joining a world-class team at Newark Beth. The center is one of the Top 15 centers in the nation and one of only 6% of centers nationwide that has performed more than 1,100 heart transplants.
Dr. Sergio Waxman, the director of cardiology, was happy to make the announcement.
“After conducting a broad national search, we are excited to welcome Dr. Feldman to our team,” he said. “We look forward to working together to enhance our scope of services and create greater access for patients across the region in need of advanced heart failure therapies and excellent cardiac care.”
Newark Beth CEO Darrell Terry shared the enthusiasm.
“Newark Beth Israel Medical Center and Children’s Hospital of New Jersey is at the forefront of delivering comprehensive cardiac care and innovative research,” he said. “We are thrilled to have Dr. Feldman join our team of experts who have dedicated themselves to building a program that consistently delivers clinical excellence.”
About Newark Beth
Newark Beth Israel Medical Center always has been at the forefront of cardiac care and heart transplant. Dr. Victor Parsonnet performed the first heart transplant in New Jersey at the facility in 1986. In 1992, Newark Beth Israel became the first center in New Jersey to employ extracorporeal membrane oxygenation. Additionally, Newark Beth Israel was the first hospital to use Left Ventricular Assist Devices in New Jersey.
Feldman’s research and expertise are in molecular mechanisms of heart failure, cardiogenic shock and heart transplantation. Additionally, he has conducted research on mechanical circulatory support devices. He has contributed to leading research, published in national and international journals, which helped engender Food and Drug Administration approval of some of the most important mechanical support devices in use today.
Feldman’s work also helped establish national and international guidelines that, in part, set the global standard of care for every advanced myocardial therapy (heart failure and heart transplant) program in the world.
Feldman also has conducted extensive research into health care disparities in cardiac care, and the impact on African American communities. He has authored numerous studies exploring how race and socioeconomic factors impact blood pressure, atherosclerosis and even readiness to adopt an exercise regimen.
Feldman is a fellow of the American Heart Association and the American College of Cardiology, and a member of the Heart Failure Society of America medical group and the International Society of Heart and Lung Transplant. He has received numerous awards, grants and accolades for his work in cardiovascular care and treatments including being named to America’s Top Cardiologist and Best Doctor’s lists.
Feldman succeeds Dr. Mark Zucker, the director of cardiothoracic transplantation who helped bring national recognition and praise for the program, but later came under scrutiny and left the medical center last fall after 31 years of service.